Alpha 2.0
Login Register
» Authors » Alan Gelenberg

Alan Gelenberg

Explore the profile of Alan Gelenberg including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 63
Followers 0
Related Specialties
Pharmacology
Psychiatry
Top 10 Co-Authors
Michael E Thase
Madhukar H Trivedi
Susan G Kornstein
James H Kocsis
Anthony J Rothschild
Michael G Aman
Jaswinder K Ghuman
David L Dunner
Edward S Friedman
Sydney Rice
Published In
J Affect Disord
J Child Adolesc Psychopharmacol
J Psychiatr Res
Psychopharmacol Bull
Affiliations
Soon will be listed here.
Recent Articles
1.
Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study
Thase M, Gelenberg A, Kornstein S, Kocsis J, Trivedi M, Ninan P, et al.
J Psychiatr Res . 2010 Aug; 45(3):412-20. PMID: 20801464
This secondary analysis from the Prevention of Recurrent Episodes of Depression with Venlafaxine Extended Release (ER) for Two Years (PREVENT) study compared the efficacy of venlafaxine ER and fluoxetine for...
2.
Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release
Trivedi M, Dunner D, Kornstein S, Thase M, Zajecka J, Rothschild A, et al.
J Affect Disord . 2010 Jun; 126(3):420-9. PMID: 20510459
Background: Psychosocial outcomes from the Prevention of Recurrent Episodes of Depression with Venlafaxine ER for Two Years (PREVENT) study were evaluated. Methods: Adult outpatients with recurrent major depressive disorder (MDD)...
3.
Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study
Rothschild A, Dunlop B, Dunner D, Friedman E, Gelenberg A, Holland P, et al.
Psychopharmacol Bull . 2009 Sep; 42(3):5-20. PMID: 19752838
Background: Antidepressant tachyphylaxis describes the return of apathetic depressive symptoms, such as fatigue and decreased motivation, despite continued use of a previously effective treatment. Methods: Data were collected from a...
4.
Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders
Ghuman J, Aman M, Lecavalier L, Riddle M, Gelenberg A, Wright R, et al.
J Child Adolesc Psychopharmacol . 2009 Aug; 19(4):329-39. PMID: 19702485
Objective: The aim of this study was to investigate the short-term efficacy and safety of methylphenidate (MPH) to treat attention-deficit/hyperactivity disorder (ADHD) symptoms in an understudied population of preschoolers with...
5.
Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder
Ghuman J, Aman M, Ghuman H, Reichenbacher T, Gelenberg A, Wright R, et al.
J Child Adolesc Psychopharmacol . 2009 Apr; 19(2):155-66. PMID: 19364293
Objective: The aim of this study was to report preliminary data regarding effectiveness and tolerability of atomoxetine in 3- to 5-year-old preschool children with attention-deficit/hyperactivity disorder (ADHD). Methods: Nine boys...
6.
Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania
Baker R, Milton D, Stauffer V, Gelenberg A, Tohen M
J Affect Disord . 2003 Jan; 73(1-2):147-53. PMID: 12507747
Background: Published case reports describe apparent induction or exacerbation of manic-like symptoms during treatment with the atypical antipsychotics olanzapine and risperidone. To date, such reports are from uncontrolled clinical experience...